De Ishani, Steffen Megan D, Clark Paul A, Patros Clayton J, Sokn Emily, Bishop Stephanie M, Litscher Suzanne, Maklakova Vilena I, Kuo John S, Rodriguez Fausto J, Collier Lara S
School of Pharmacy, Carbone Cancer Center and the Molecular and Cellular Pharmacology Graduate Program, University of Wisconsin-Madison, Madison, Wisconsin.
Department of Neurological Surgery and Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Cancer Res. 2016 May 1;76(9):2552-60. doi: 10.1158/0008-5472.CAN-15-2386. Epub 2016 Mar 24.
Current therapies for high-grade gliomas extend survival only modestly. The glioma microenvironment, including glioma-associated microglia/macrophages (GAM), is a potential therapeutic target. The microglia/macrophage cytokine CSF1 and its receptor CSF1R are overexpressed in human high-grade gliomas. To determine whether the other known CSF1R ligand IL34 is expressed in gliomas, we examined expression array data of human high-grade gliomas and performed RT-PCR on glioblastoma sphere-forming cell lines (GSC). Expression microarray analyses indicated that CSF1, but not IL34, is frequently overexpressed in human tumors. We found that while GSCs did express CSF1, most GSC lines did not express detectable levels of IL34 mRNA. We therefore studied the impact of modulating CSF1 levels on gliomagenesis in the context of the GFAP-V12Ha-ras-IRESLacZ (Ras*) model. Csf1 deficiency deterred glioma formation in the Ras* model, whereas CSF1 transgenic overexpression decreased the survival of Ras* mice and promoted the formation of high-grade gliomas. Conversely, CSF1 overexpression increased GAM density, but did not impact GAM polarization state. Regardless of CSF1 expression status, most GAMs were negative for the M2 polarization markers ARG1 and CD206; when present, ARG1(+) and CD206(+) cells were found in regions of peripheral immune cell invasion. Therefore, our findings indicate that CSF1 signaling is oncogenic during gliomagenesis through a mechanism distinct from modulating GAM polarization status. Cancer Res; 76(9); 2552-60. ©2016 AACR.
目前针对高级别胶质瘤的治疗方法仅能适度延长生存期。胶质瘤微环境,包括胶质瘤相关小胶质细胞/巨噬细胞(GAM),是一个潜在的治疗靶点。小胶质细胞/巨噬细胞细胞因子集落刺激因子1(CSF1)及其受体CSF1R在人类高级别胶质瘤中过表达。为了确定另一种已知的CSF1R配体白细胞介素34(IL34)是否在胶质瘤中表达,我们检测了人类高级别胶质瘤的表达阵列数据,并对胶质母细胞瘤成球细胞系(GSC)进行了逆转录聚合酶链反应(RT-PCR)。表达微阵列分析表明,CSF1而非IL34在人类肿瘤中经常过表达。我们发现,虽然GSC确实表达CSF1,但大多数GSC系未表达可检测水平的IL34 mRNA。因此,我们在胶质纤维酸性蛋白-V12Ha- ras - IRES LacZ(Ras*)模型的背景下研究了调节CSF1水平对胶质瘤发生的影响。Csf1缺陷在Ras模型中抑制了胶质瘤的形成,而CSF1转基因过表达降低了Ras小鼠的存活率并促进了高级别胶质瘤的形成。相反,CSF1过表达增加了GAM密度,但不影响GAM极化状态。无论CSF1表达状态如何,大多数GAM对M2极化标志物精氨酸酶1(ARG1)和CD206均呈阴性;当存在时,ARG1(+)和CD206(+)细胞出现在外周免疫细胞浸润区域。因此,我们的研究结果表明,CSF1信号在胶质瘤发生过程中具有致癌作用,其机制不同于调节GAM极化状态。《癌症研究》;76(9);2552 - 2560。©2016美国癌症研究协会。